\n \n\n \n \n \n \n \n \n Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of New Zealand doctors in an oncology setting.\n \n \n \n \n\n\n \n Oldfield, K.; Eathorne, A.; Tewhaiti-Smith, J.; Beasley, R.; Semprini, A.; and Braithwaite, I.\n\n\n \n\n\n\n Postgraduate Medical Journal,postgradmedj–2020–139013. November 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Experiences,$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{oldfield_experiences_2020,\n\ttitle = {Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of {New} {Zealand} doctors in an oncology setting},\n\tissn = {0032-5473, 1469-0756},\n\turl = {https://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2020-139013},\n\tdoi = {10.1136/postgradmedj-2020-139013},\n\tabstract = {Purpose of Study\n              To explore the experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in New Zealand doctors in an oncology setting.\n            \n            \n              Study Design\n              An observational cross-sectional survey undertaken between November 2019 and January 2020 across four secondary-care hospital oncology departments within New Zealand (Auckland, Wellington, Christchurch and Dunedin). Participants were a convenience sample of doctors; consultants, registrars, medical officers of special status and house surgeons working in oncology departments. Of 53 individuals approached, 45 participated (85\\% Response Rate). The primary outcome was reporteddoctor-patient interactions. Secondary outcomes included knowledge of cannabis-based products, their efficacy, prescribing regulations and educational access.\n            \n            \n              Results\n              Of 44 doctors, 37 (84\\%, 95\\% CI: 70 to 93) reported patient requests to prescribe cannabis-based products and 43 (98\\%, 95\\% CI: 88 to 100) reported patients using illicit cannabis for medical symptoms. Primary request reasons were pain, nausea/vomiting and cancer treatment. 33/45 (73\\%, 95\\% CI: 58 to 85) cited knowledge of at least one cannabis-based product and 27/45 (60\\%, 95\\% CI: 44 to 74) indicated at least one condition that had evidence of efficacy. 36/44 (82\\%, 95\\% CI: 67 to 92) expressed future prescribing concerns but all were willing to use a cannabis-based product developed with traditional medical provenance.\n            \n            \n              Conclusion\n              In the oncology setting, patients are asking doctors about symptomatic and curative treatment with cannabis-based products. Doctors are not biased against the use of products showing medical provenance; however, NZ-specific clinical and regulatory guidelines are essential to support patient discussions and appropriate prescribing.},\n\tlanguage = {en},\n\turldate = {2021-06-08},\n\tjournal = {Postgraduate Medical Journal},\n\tauthor = {Oldfield, Karen and Eathorne, Allie and Tewhaiti-Smith, Jordan and Beasley, Richard and Semprini, Alex and Braithwaite, Irene},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {postgradmedj--2020--139013},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Knowledge and perspectives about the use of cannabis as a medicine: a mixed methods observational study in a cohort of New Zealand general practice patients.\n \n \n \n\n\n \n Oldfield, K.; Eathorne, A.; Maijers, I.; Beasley, R.; Semprini, A.; and Braithwaite, I.\n\n\n \n\n\n\n The New Zealand Medical Journal, 133(1522): 96–111. September 2020.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{oldfield_knowledge_2020,\n\ttitle = {Knowledge and perspectives about the use of cannabis as a medicine: a mixed methods observational study in a cohort of {New} {Zealand} general practice patients},\n\tvolume = {133},\n\tissn = {1175-8716},\n\tshorttitle = {Knowledge and perspectives about the use of cannabis as a medicine},\n\tabstract = {AIM: To determine what patients presenting to general practice (GP) understand about the use of cannabis as a medicine, beliefs of how this may impact their medical conditions and interactions with doctors.\nMETHOD: An in-person survey of 134 GP patients from four GP practices throughout the North Island of New Zealand undertaken from November 2018 to October 2019.\nRESULTS: Fifty-five percent of the sample were female, with 40\\% of all participants aged 60 years plus. Ninety-one percent of participants indicated they would use a prescribed medicinal cannabis product while 45\\% reported they believed it may be of some benefit to their medical condition. Of those who believed it beneficial, 71\\% indicated they thought it useful for pain relief. Participants indicated comfort discussing medicinal cannabis use with GPs and specialists (92\\% respectively); however, less than 10\\% had done this.\nCONCLUSIONS: Just under half of patients surveyed believe that medicinal cannabis products may be helpful to their condition, and while the majority report willingness, few have discussed this with their GP or specialist. There is need for accessible, accurate information regarding the use of cannabis-based medicine for patients and doctors alike to guide the patient-doctor consultation and decrease barriers to open discussion.},\n\tlanguage = {eng},\n\tnumber = {1522},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Oldfield, Karen and Eathorne, Allie and Maijers, Ingrid and Beasley, Richard and Semprini, Alex and Braithwaite, Irene},\n\tmonth = sep,\n\tyear = {2020},\n\tpmid = {32994620},\n\tkeywords = {Adult, Aged, Aged, 80 and over, Female, General Practice, Health Knowledge, Attitudes, Practice, Humans, Male, Medical Marijuana, Middle Aged, New Zealand, Pain Management, Prospective Studies, Surveys and Questionnaires, Young Adult},\n\tpages = {96--111},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Could stress ulcer prophylaxis increase mortality in high-acuity patients?.\n \n \n \n \n\n\n \n Harhay, M. O.; Young, P. J.; and Shankar-Hari, M.\n\n\n \n\n\n\n Intensive Care Medicine, 46(4): 793–795. April 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Could$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{harhay_could_2020,\n\ttitle = {Could stress ulcer prophylaxis increase mortality in high-acuity patients?},\n\tvolume = {46},\n\tissn = {0342-4642, 1432-1238},\n\turl = {http://link.springer.com/10.1007/s00134-020-05959-x},\n\tdoi = {10.1007/s00134-020-05959-x},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2021-05-20},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Harhay, Michael O. and Young, Paul J. and Shankar-Hari, Manu},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {793--795},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Outcomes of patients with subarachnoid haemorrhage admitted to Australian and New Zealand intensive care units following a cardiac arrest.\n \n \n \n\n\n \n Heaney, J.; Paul, E.; Pilcher, D.; Lin, C.; Udy, A.; and Young, P. J.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 22(3): 237–244. September 2020.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{heaney_outcomes_2020,\n\ttitle = {Outcomes of patients with subarachnoid haemorrhage admitted to {Australian} and {New} {Zealand} intensive care units following a cardiac arrest},\n\tvolume = {22},\n\tissn = {1441-2772},\n\tabstract = {OBJECTIVES: To describe the characteristics and outcomes of adults with a subarachnoid haemorrhage (SAH) admitted to Australian and New Zealand intensive care units (ICUs) with a cardiac arrest in the preceding 24 hours.\nDESIGN: Retrospective cohort study.\nSETTING: Study data from 144 Australian and New Zealand ICUs were obtained from the Australian and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Adult Patient Database.\nPARTICIPANTS: A total of 439 of 11 047 (3.9\\%) patients admitted to an ICU with a SAH had a documented cardiac arrest in the 24 hours preceding their ICU admission. The mean age of patients with SAH and a preceding cardiac arrest was 55.3 years (SD, 13.7) and 251 of 439 (57.2\\%) were female.\nMAIN OUTCOME MEASURES: The primary outcome of interest was in-hospital mortality. Key secondary outcomes were ICU mortality, ICU and hospital lengths of stay, the proportion of patients discharged home.\nRESULTS: SAH patients with a history of cardiac arrest preceding ICU admission had a higher mortality rate (81.5\\% v 23.3\\%; P {\\textless} 0.0001) and a lower rate of discharge home (4.6\\% v 37.0\\%; P {\\textless} 0.0001) compared with patients with SAH who did not have a cardiac arrest. Among patients with SAH who had a cardiac arrest and survived, 20 of 81 (24.7\\%) were discharged home. In SAH patients with cardiac arrest, having a GCS of 3, the Australian and New Zealand Risk of Death score, and being admitted to ICU for palliative care or organ donation were significant predictors of in-hospital death.\nCONCLUSIONS: Almost one in five SAH patients who had a documented cardiac arrest in the 24 hours preceding ICU admission to an Australian and New Zealand ICU survived to hospital discharge, with around a quarter of these survivors discharged home. The neurological outcomes of these patients are uncertain, and understanding the burden of disability in survivors is an important area for further research.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Heaney, Jonathan and Paul, Eldho and Pilcher, David and Lin, Caleb and Udy, Andrew and Young, Paul J.},\n\tmonth = sep,\n\tyear = {2020},\n\tpmid = {32900330},\n\tkeywords = {Adult, Australia, Databases, Factual, Female, Heart Arrest, Hospital Mortality, Humans, Intensive Care Units, Length of Stay, Male, Middle Aged, New Zealand, Retrospective Studies, Subarachnoid Hemorrhage},\n\tpages = {237--244},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Avoidance of Routine Endotracheal Suction in Subjects Ventilated for ≤ 12 h Following Elective Cardiac Surgery.\n \n \n \n \n\n\n \n Gilder, E.; McGuinness, S. P; Cavadino, A.; Jull, A.; and Parke, R. L\n\n\n \n\n\n\n Respiratory Care,respcare.07821. August 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Avoidance$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{gilder_avoidance_2020,\n\ttitle = {Avoidance of {Routine} {Endotracheal} {Suction} in {Subjects} {Ventilated} for ≤ 12 h {Following} {Elective} {Cardiac} {Surgery}},\n\tissn = {0020-1324, 1943-3654},\n\turl = {http://rc.rcjournal.com/lookup/doi/10.4187/respcare.07821},\n\tdoi = {10.4187/respcare.07821},\n\tlanguage = {en},\n\turldate = {2021-05-12},\n\tjournal = {Respiratory Care},\n\tauthor = {Gilder, Eileen and McGuinness, Shay P and Cavadino, Alana and Jull, Andrew and Parke, Rachael L},\n\tmonth = aug,\n\tyear = {2020},\n\tpages = {respcare.07821},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.\n \n \n \n \n\n\n \n Fujii, T.; Luethi, N.; Young, P. J.; Frei, D. R.; Eastwood, G. M.; French, C. J.; Deane, A. M.; Shehabi, Y.; Hajjar, L. A.; Oliveira, G.; Udy, A. A.; Orford, N.; Edney, S. J.; Hunt, A. L.; Judd, H. L.; Bitker, L.; Cioccari, L.; Naorungroj, T.; Yanase, F.; Bates, S.; McGain, F.; Hudson, E. P.; Al-Bassam, W.; Dwivedi, D. B.; Peppin, C.; McCracken, P.; Orosz, J.; Bailey, M.; Bellomo, R.; and for the VITAMINS Trial Investigators\n\n\n \n\n\n\n JAMA, 323(5): 423. February 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Effect$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{fujii_effect_2020,\n\ttitle = {Effect of {Vitamin} {C}, {Hydrocortisone}, and {Thiamine} vs {Hydrocortisone} {Alone} on {Time} {Alive} and {Free} of {Vasopressor} {Support} {Among} {Patients} {With} {Septic} {Shock}: {The} {VITAMINS} {Randomized} {Clinical} {Trial}},\n\tvolume = {323},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of {Vitamin} {C}, {Hydrocortisone}, and {Thiamine} vs {Hydrocortisone} {Alone} on {Time} {Alive} and {Free} of {Vasopressor} {Support} {Among} {Patients} {With} {Septic} {Shock}},\n\turl = {https://jamanetwork.com/journals/jama/fullarticle/2759414},\n\tdoi = {10.1001/jama.2019.22176},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2021-05-12},\n\tjournal = {JAMA},\n\tauthor = {Fujii, Tomoko and Luethi, Nora and Young, Paul J. and Frei, Daniel R. and Eastwood, Glenn M. and French, Craig J. and Deane, Adam M. and Shehabi, Yahya and Hajjar, Ludhmila A. and Oliveira, Gisele and Udy, Andrew A. and Orford, Neil and Edney, Samantha J. and Hunt, Anna L. and Judd, Harriet L. and Bitker, Laurent and Cioccari, Luca and Naorungroj, Thummaporn and Yanase, Fumitaka and Bates, Samantha and McGain, Forbes and Hudson, Elizabeth P. and Al-Bassam, Wisam and Dwivedi, Dhiraj Bhatia and Peppin, Chloe and McCracken, Phoebe and Orosz, Judit and Bailey, Michael and Bellomo, Rinaldo and {for the VITAMINS Trial Investigators}},\n\tmonth = feb,\n\tyear = {2020},\n\tpages = {423},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Where to from here with recommendations for perioperative oxygen therapy?.\n \n \n \n \n\n\n \n Frei, D.; and Young, P. J.\n\n\n \n\n\n\n Anaesthesia Critical Care & Pain Medicine, 39(6): 755–757. December 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Where$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{frei_where_2020,\n\ttitle = {Where to from here with recommendations for perioperative oxygen therapy?},\n\tvolume = {39},\n\tissn = {23525568},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2352556820302381},\n\tdoi = {10.1016/j.accpm.2020.07.022},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2021-05-12},\n\tjournal = {Anaesthesia Critical Care \\& Pain Medicine},\n\tauthor = {Frei, Daniel and Young, Paul J.},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {755--757},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Patient experiences of as-needed budesonide-formoterol by Turbuhaler® for treatment of mild asthma; a qualitative study.\n \n \n \n \n\n\n \n Foster, J.; Beasley, R.; Braithwaite, I.; Harrison, T.; Holliday, M.; Pavord, I.; and Reddel, H.\n\n\n \n\n\n\n Respiratory Medicine, 175: 106154. December 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Patient$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{foster_patient_2020,\n\ttitle = {Patient experiences of as-needed budesonide-formoterol by {Turbuhaler}® for treatment of mild asthma; a qualitative study},\n\tvolume = {175},\n\tissn = {09546111},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0954611120302948},\n\tdoi = {10.1016/j.rmed.2020.106154},\n\tlanguage = {en},\n\turldate = {2021-05-12},\n\tjournal = {Respiratory Medicine},\n\tauthor = {Foster, J.M. and Beasley, R. and Braithwaite, I. and Harrison, T. and Holliday, M. and Pavord, I. and Reddel, H.K.},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {106154},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Outcomes Six Months after Delivering 100% or 70% of Enteral Calorie Requirements during Critical Illness (TARGET). A Randomized Controlled Trial.\n \n \n \n \n\n\n \n Deane, A. M.; Little, L.; Bellomo, R.; Chapman, M. J.; Davies, A. R.; Ferrie, S.; Horowitz, M.; Hurford, S.; Lange, K.; Litton, E.; Mackle, D.; O’Connor, S.; Parker, J.; Peake, S. L.; Presneill, J. J.; Ridley, E. J.; Singh, V.; van Haren, F.; Williams, P.; Young, P.; and Iwashyna, T. J.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 201(7): 814–822. April 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Outcomes$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{deane_outcomes_2020,\n\ttitle = {Outcomes {Six} {Months} after {Delivering} 100\\% or 70\\% of {Enteral} {Calorie} {Requirements} during {Critical} {Illness} ({TARGET}). {A} {Randomized} {Controlled} {Trial}},\n\tvolume = {201},\n\tissn = {1073-449X, 1535-4970},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.201909-1810OC},\n\tdoi = {10.1164/rccm.201909-1810OC},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2021-05-12},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Deane, Adam M. and Little, Lorraine and Bellomo, Rinaldo and Chapman, Marianne J. and Davies, Andrew R. and Ferrie, Suzie and Horowitz, Michael and Hurford, Sally and Lange, Kylie and Litton, Edward and Mackle, Diane and O’Connor, Stephanie and Parker, Jane and Peake, Sandra L. and Presneill, Jeffrey J. and Ridley, Emma J. and Singh, Vanessa and van Haren, Frank and Williams, Patricia and Young, Paul and Iwashyna, Theodore J.},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {814--822},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Frailty and mortality in patients with COVID-19.\n \n \n \n \n\n\n \n Darvall, J. N; Bellomo, R.; Young, P. J; Rockwood, K.; and Pilcher, D.\n\n\n \n\n\n\n The Lancet Public Health, 5(11): e580. November 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Frailty$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{darvall_frailty_2020,\n\ttitle = {Frailty and mortality in patients with {COVID}-19},\n\tvolume = {5},\n\tissn = {24682667},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2468266720302280},\n\tdoi = {10.1016/S2468-2667(20)30228-0},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2021-05-07},\n\tjournal = {The Lancet Public Health},\n\tauthor = {Darvall, Jai N and Bellomo, Rinaldo and Young, Paul J and Rockwood, Kenneth and Pilcher, David},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {e580},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Frailty and outcomes from pneumonia in critical illness: a population-based cohort study.\n \n \n \n \n\n\n \n Darvall, J. N.; Bellomo, R.; Bailey, M.; Paul, E.; Young, P. J.; Rockwood, K.; and Pilcher, D.\n\n\n \n\n\n\n British Journal of Anaesthesia, 125(5): 730–738. November 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Frailty$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{darvall_frailty_2020-1,\n\ttitle = {Frailty and outcomes from pneumonia in critical illness: a population-based cohort study},\n\tvolume = {125},\n\tissn = {00070912},\n\tshorttitle = {Frailty and outcomes from pneumonia in critical illness},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0007091220306425},\n\tdoi = {10.1016/j.bja.2020.07.049},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2021-05-07},\n\tjournal = {British Journal of Anaesthesia},\n\tauthor = {Darvall, Jai N. and Bellomo, Rinaldo and Bailey, Michael and Paul, Eldho and Young, Paul J. and Rockwood, Kenneth and Pilcher, David},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {730--738},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia.\n \n \n \n \n\n\n \n Conway, A.; Collins, P.; Chang, K.; Mafeld, S.; Sutherland, J.; Fingleton, J.; and Parotto, M.\n\n\n \n\n\n\n Journal of Clinical Monitoring and Computing, 34(5): 1061–1068. October 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Pre-apneic$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{conway_pre-apneic_2020,\n\ttitle = {Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia},\n\tvolume = {34},\n\tissn = {1387-1307, 1573-2614},\n\turl = {http://link.springer.com/10.1007/s10877-019-00391-z},\n\tdoi = {10.1007/s10877-019-00391-z},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2021-05-07},\n\tjournal = {Journal of Clinical Monitoring and Computing},\n\tauthor = {Conway, Aaron and Collins, Peter and Chang, Kristina and Mafeld, Sebastian and Sutherland, Joanna and Fingleton, James and Parotto, Matteo},\n\tmonth = oct,\n\tyear = {2020},\n\tpages = {1061--1068},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n The effect of conservative oxygen therapy on systemic biomarkers of oxidative stress in critically ill patients.\n \n \n \n \n\n\n \n Carr, A. C.; Spencer, E.; Mackle, D.; Hunt, A.; Judd, H.; Mehrtens, J.; Parker, K.; Stockwell, Z.; Gale, C.; Beaumont, M.; Kaur, S.; Bihari, S.; and Young, P. J.\n\n\n \n\n\n\n Free Radical Biology and Medicine, 160: 13–18. November 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"The$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{carr_effect_2020,\n\ttitle = {The effect of conservative oxygen therapy on systemic biomarkers of oxidative stress in critically ill patients},\n\tvolume = {160},\n\tissn = {08915849},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0891584920311151},\n\tdoi = {10.1016/j.freeradbiomed.2020.06.018},\n\tlanguage = {en},\n\turldate = {2021-05-07},\n\tjournal = {Free Radical Biology and Medicine},\n\tauthor = {Carr, Anitra C. and Spencer, Emma and Mackle, Diane and Hunt, Anna and Judd, Harriet and Mehrtens, Jan and Parker, Kim and Stockwell, Zoe and Gale, Caitlin and Beaumont, Megan and Kaur, Simran and Bihari, Shailesh and Young, Paul J.},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {13--18},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Treatment for Pneumothorax.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n New England Journal of Medicine, 382(18): 1765–1767. April 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Treatment$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{noauthor_treatment_2020,\n\ttitle = {Treatment for {Pneumothorax}},\n\tvolume = {382},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMc2003612},\n\tdoi = {10.1056/NEJMc2003612},\n\tlanguage = {en},\n\tnumber = {18},\n\turldate = {2021-05-07},\n\tjournal = {New England Journal of Medicine},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {1765--1767},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis.\n \n \n \n \n\n\n \n Bhagavan, C.; Kung, S.; Doppen, M.; John, M.; Vakalalabure, I.; Oldfield, K.; Braithwaite, I.; and Newton-Howes, G.\n\n\n \n\n\n\n CNS Drugs, 34(12): 1217–1228. December 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Cannabinoids$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{bhagavan_cannabinoids_2020,\n\ttitle = {Cannabinoids in the {Treatment} of {Insomnia} {Disorder}: {A} {Systematic} {Review} and {Meta}-{Analysis}},\n\tvolume = {34},\n\tissn = {1172-7047, 1179-1934},\n\tshorttitle = {Cannabinoids in the {Treatment} of {Insomnia} {Disorder}},\n\turl = {http://link.springer.com/10.1007/s40263-020-00773-x},\n\tdoi = {10.1007/s40263-020-00773-x},\n\tlanguage = {en},\n\tnumber = {12},\n\turldate = {2021-05-07},\n\tjournal = {CNS Drugs},\n\tauthor = {Bhagavan, Chiranth and Kung, Stacey and Doppen, Marjan and John, Mary and Vakalalabure, Iva and Oldfield, Karen and Braithwaite, Irene and Newton-Howes, Giles},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {1217--1228},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Characteristics and Outcomes of Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Australia and New Zealand.\n \n \n \n \n\n\n \n Berenyi, F.; Steinfort, D. P.; Abdelhamid, Y. A.; Bailey, M. J.; Pilcher, D. V.; Bellomo, R.; Finnis, M. E.; Young, P. J.; and Deane, A. M.\n\n\n \n\n\n\n Annals of the American Thoracic Society, 17(6): 736–745. June 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Characteristics$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{berenyi_characteristics_2020,\n\ttitle = {Characteristics and {Outcomes} of {Critically} {Ill} {Patients} with {Acute} {Exacerbation} of {Chronic} {Obstructive} {Pulmonary} {Disease} in {Australia} and {New} {Zealand}},\n\tvolume = {17},\n\tissn = {2329-6933, 2325-6621},\n\turl = {https://www.atsjournals.org/doi/10.1513/AnnalsATS.201911-821OC},\n\tdoi = {10.1513/AnnalsATS.201911-821OC},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2021-05-07},\n\tjournal = {Annals of the American Thoracic Society},\n\tauthor = {Berenyi, Freya and Steinfort, Daniel P. and Abdelhamid, Yasmine Ali and Bailey, Michael J. and Pilcher, David V. and Bellomo, Rinaldo and Finnis, Mark E. and Young, Paul J. and Deane, Adam M.},\n\tmonth = jun,\n\tyear = {2020},\n\tpages = {736--745},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.\n \n \n \n \n\n\n \n Bellomo, R.; Wunderink, R. G.; Szerlip, H.; English, S. W.; Busse, L. W.; Deane, A. M.; Khanna, A. K.; McCurdy, M. T.; Ostermann, M.; Young, P. J.; Handisides, D. R.; Chawla, L. S.; Tidmarsh, G. F.; and Albertson, T. E.\n\n\n \n\n\n\n Critical Care, 24(1): 43. December 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Angiotensin$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{bellomo_angiotensin_2020,\n\ttitle = {Angiotensin {I} and angiotensin {II} concentrations and their ratio in catecholamine-resistant vasodilatory shock},\n\tvolume = {24},\n\tissn = {1364-8535},\n\turl = {https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-2733-x},\n\tdoi = {10.1186/s13054-020-2733-x},\n\tabstract = {Abstract\n            \n              Background\n              In patients with vasodilatory shock, plasma concentrations of angiotensin I (ANG I) and II (ANG II) and their ratio may reflect differences in the response to severe vasodilation, provide novel insights into its biology, and predict clinical outcomes. The objective of these protocol prespecified and subsequent post hoc analyses was to assess the epidemiology and outcome associations of plasma ANG I and ANG II levels and their ratio in patients with catecholamine-resistant vasodilatory shock (CRVS) enrolled in the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study.\n            \n            \n              Methods\n              We measured ANG I and ANG II levels at baseline, calculated their ratio, and compared these results to values from healthy volunteers (controls). We dichotomized patients according to the median ANG I/II ratio (1.63) and compared demographics, clinical characteristics, and clinical outcomes. We constructed a Cox proportional hazards model to test the independent association of ANG I, ANG II, and their ratio with clinical outcomes.\n            \n            \n              Results\n              \n                Median baseline ANG I level (253 pg/mL [interquartile range (IQR) 72.30–676.00 pg/mL] vs 42 pg/mL [IQR 30.46–87.34 pg/mL] in controls;\n                P\n                 {\\textless}  0.0001) and median ANG I/II ratio (1.63 [IQR 0.98–5.25] vs 0.4 [IQR 0.28–0.64] in controls;\n                P\n                 {\\textless}  0.0001) were elevated, whereas median ANG II levels were similar (84 pg/mL [IQR 23.85–299.50 pg/mL] vs 97 pg/mL [IQR 35.27–181.01 pg/mL] in controls;\n                P\n                 = 0.9895). At baseline, patients with a ratio above the median (≥1.63) had higher ANG I levels (\n                P\n                 {\\textless}  0.0001), lower ANG II levels (\n                P\n                 {\\textless}  0.0001), higher albumin concentrations (\n                P\n                 = 0.007), and greater incidence of recent (within 1 week) exposure to angiotensin-converting enzyme inhibitors (\n                P\n                 {\\textless}  0.00001), and they received a higher norepinephrine-equivalent dose (\n                P\n                 = 0.003). In the placebo group, a baseline ANG I/II ratio {\\textless}1.63 was associated with improved survival (hazard ratio 0.56; 95\\% confidence interval 0.36–0.88;\n                P\n                 = 0.01) on unadjusted analyses.\n              \n            \n            \n              Conclusions\n              Patients with CRVS have elevated ANG I levels and ANG I/II ratios compared with healthy controls. In such patients, a high ANG I/II ratio is associated with greater norepinephrine requirements and is an independent predictor of mortality, thus providing a biological rationale for interventions aimed at its correction.\n            \n            \n              Trial registration\n              \n                ClinicalTrials.gov identifier\n                NCT02338843\n                . Registered 14 January 2015.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-05-07},\n\tjournal = {Critical Care},\n\tauthor = {Bellomo, Rinaldo and Wunderink, Richard G. and Szerlip, Harold and English, Shane W. and Busse, Laurence W. and Deane, Adam M. and Khanna, Ashish K. and McCurdy, Michael T. and Ostermann, Marlies and Young, Paul J. and Handisides, Damian R. and Chawla, Lakhmir S. and Tidmarsh, George F. and Albertson, Timothy E.},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {43},\n}\n\n

\n

\n\n\n

\n Abstract Background In patients with vasodilatory shock, plasma concentrations of angiotensin I (ANG I) and II (ANG II) and their ratio may reflect differences in the response to severe vasodilation, provide novel insights into its biology, and predict clinical outcomes. The objective of these protocol prespecified and subsequent post hoc analyses was to assess the epidemiology and outcome associations of plasma ANG I and ANG II levels and their ratio in patients with catecholamine-resistant vasodilatory shock (CRVS) enrolled in the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study. Methods We measured ANG I and ANG II levels at baseline, calculated their ratio, and compared these results to values from healthy volunteers (controls). We dichotomized patients according to the median ANG I/II ratio (1.63) and compared demographics, clinical characteristics, and clinical outcomes. We constructed a Cox proportional hazards model to test the independent association of ANG I, ANG II, and their ratio with clinical outcomes. Results Median baseline ANG I level (253 pg/mL [interquartile range (IQR) 72.30–676.00 pg/mL] vs 42 pg/mL [IQR 30.46–87.34 pg/mL] in controls; P \\textless 0.0001) and median ANG I/II ratio (1.63 [IQR 0.98–5.25] vs 0.4 [IQR 0.28–0.64] in controls; P \\textless 0.0001) were elevated, whereas median ANG II levels were similar (84 pg/mL [IQR 23.85–299.50 pg/mL] vs 97 pg/mL [IQR 35.27–181.01 pg/mL] in controls; P = 0.9895). At baseline, patients with a ratio above the median (≥1.63) had higher ANG I levels ( P \\textless 0.0001), lower ANG II levels ( P \\textless 0.0001), higher albumin concentrations ( P = 0.007), and greater incidence of recent (within 1 week) exposure to angiotensin-converting enzyme inhibitors ( P \\textless 0.00001), and they received a higher norepinephrine-equivalent dose ( P = 0.003). In the placebo group, a baseline ANG I/II ratio \\textless1.63 was associated with improved survival (hazard ratio 0.56; 95% confidence interval 0.36–0.88; P = 0.01) on unadjusted analyses. Conclusions Patients with CRVS have elevated ANG I levels and ANG I/II ratios compared with healthy controls. In such patients, a high ANG I/II ratio is associated with greater norepinephrine requirements and is an independent predictor of mortality, thus providing a biological rationale for interventions aimed at its correction. Trial registration ClinicalTrials.gov identifier NCT02338843 . Registered 14 January 2015.\n

\n\n\n

\n \n\n \n \n \n \n \n \n Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice.\n \n \n \n \n\n\n \n Beasley, R.; Harper, J.; and Masoli, M.\n\n\n \n\n\n\n The Lancet Respiratory Medicine, 8(5): 425–427. May 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Anti-interleukin-5$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_anti-interleukin-5_2020,\n\ttitle = {Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice},\n\tvolume = {8},\n\tissn = {22132600},\n\tshorttitle = {Anti-interleukin-5 therapy in patients with severe asthma},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260020300515},\n\tdoi = {10.1016/S2213-2600(20)30051-5},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2021-05-07},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Harper, James and Masoli, Matthew},\n\tmonth = may,\n\tyear = {2020},\n\tpages = {425--427},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Twenty‐five years of Respirology: Advances in asthma.\n \n \n \n \n\n\n \n Beasley, R.; and Gibson, P.\n\n\n \n\n\n\n Respirology, 25(1): 11–13. January 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Twenty‐five$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_twentyfive_2020,\n\ttitle = {Twenty‐five years of {Respirology}: {Advances} in asthma},\n\tvolume = {25},\n\tissn = {1323-7799, 1440-1843},\n\tshorttitle = {Twenty‐five years of \\textit{{Respirology}}},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13735},\n\tdoi = {10.1111/resp.13735},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-05-07},\n\tjournal = {Respirology},\n\tauthor = {Beasley, Richard and Gibson, Peter},\n\tmonth = jan,\n\tyear = {2020},\n\tpages = {11--13},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma.\n \n \n \n \n\n\n \n Beasley, R.; Braithwaite, I.; Semprini, A.; Kearns, C.; Weatherall, M.; Harrison, T. W.; Papi, A.; and Pavord, I. D.\n\n\n \n\n\n\n European Respiratory Journal, 55(1): 1901407. January 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"ICS-formoterol$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_ics-formoterol_2020,\n\ttitle = {{ICS}-formoterol reliever therapy stepwise treatment algorithm for adult asthma},\n\tvolume = {55},\n\tissn = {0903-1936, 1399-3003},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01407-2019},\n\tdoi = {10.1183/13993003.01407-2019},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-05-07},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Beasley, Richard and Braithwaite, Irene and Semprini, Alex and Kearns, Ciléin and Weatherall, Mark and Harrison, Tim W. and Papi, Alberto and Pavord, Ian D.},\n\tmonth = jan,\n\tyear = {2020},\n\tpages = {1901407},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial.\n \n \n \n \n\n\n \n Baggott, C.; Reddel, H. K.; Hardy, J.; Sparks, J.; Holliday, M.; Corin, A.; Montgomery, B.; Reid, J.; Sheahan, D.; Hancox, R. J.; Weatherall, M.; Beasley, R.; and Fingleton, J.\n\n\n \n\n\n\n European Respiratory Journal, 55(4): 1902073. April 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Patient$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{baggott_patient_2020,\n\ttitle = {Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the {PRACTICAL} study, a randomised clinical trial},\n\tvolume = {55},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02073-2019},\n\tdoi = {10.1183/13993003.02073-2019},\n\tabstract = {Symptom-driven low-dose inhaled corticosteroid–formoterol is safe and effective in mild asthma and has been recommended as one of the preferred treatment regimens at steps 1 and 2 in the 2019 update of the Global Initiative for Asthma. However, there are no data on patient preferences for this regimen.\n            A subgroup of participants in the PRACTICAL study (ACTRN12616000377437), a randomised controlled trial comparing symptom-driven budesonide–formoterol with maintenance budesonide plus as-needed terbutaline completed a survey on treatment preferences, satisfaction, beliefs and experience at their final study visit.\n            306 (75\\%) out of 407 eligible participants completed the survey. Regimen preference was strongly associated with randomised treatment, as were preferences for and beliefs about preventer inhaler use. Combination preventer and reliever as-needed therapy was preferred by 135 (90\\%, 95\\% CI 85.2–94.8\\%) out of 150 who were randomised to as-needed budesonide–formoterol, and by 63 (40\\%, 95\\% CI 32.7–48.1\\%) out of 156 who were randomised to maintenance budesonide. By contrast, twice-daily preventer inhaler with a reliever inhaler as required was preferred by 15 (10\\%) out of 150 of those randomised to as-needed budesonide–formoterol and 93 (60\\%) out of 156 of those randomised to maintenance budesonide. Satisfaction with all study inhalers was high. Of patients randomised to as-needed budesonide–formoterol 92\\% (n=138) were confident using it as a reliever at the end of the study.\n            Although most participants preferred the regimen to which they had been randomised, this association was much stronger for those randomised to budesonide–formoterol as needed, indicating that most patients preferred as-needed corticosteroid–formoterol therapy if they had experienced it.},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2021-05-07},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Baggott, Christina and Reddel, Helen K. and Hardy, Jo and Sparks, Jenny and Holliday, Mark and Corin, Andrew and Montgomery, Barney and Reid, Jim and Sheahan, Davitt and Hancox, Robert J. and Weatherall, Mark and Beasley, Richard and Fingleton, James},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {1902073},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n What matters most to patients when choosing treatment for mild–moderate asthma? Results from a discrete choice experiment.\n \n \n \n \n\n\n \n Baggott, C.; Hansen, P.; Hancox, R. J; Hardy, J. K.; Sparks, J.; Holliday, M.; Weatherall, M.; Beasley, R.; Reddel, H. K; and Fingleton, J.\n\n\n \n\n\n\n Thorax, 75(10): 842–848. October 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"What$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{baggott_what_2020,\n\ttitle = {What matters most to patients when choosing treatment for mild–moderate asthma? {Results} from a discrete choice experiment},\n\tvolume = {75},\n\tissn = {0040-6376, 1468-3296},\n\tshorttitle = {What matters most to patients when choosing treatment for mild–moderate asthma?},\n\turl = {https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2019-214343},\n\tdoi = {10.1136/thoraxjnl-2019-214343},\n\tabstract = {Background\n              An as-needed combination preventer and reliever regimen was recently introduced as an alternative to conventional daily preventer treatment for mild asthma. In a subgroup analysis of the PRACTICAL study, a pragmatic randomised controlled trial of budesonide–formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild asthma, we recently reported that about two-thirds preferred as-needed combination preventer and reliever therapy. The aim of this study was to determine the relative importance of attributes associated with these two asthma therapies in this subgroup of participants who indicated their preferred treatment in the PRACTICAL study.\n            \n            \n              Methods\n              At their final study visit, a subgroup of participants indicated their preferred treatment and completed a discrete choice experiment using the Potentially All Pairwise RanKings of all possible Alternatives method and 1000minds software. Treatment attributes and their levels were selected from measurable study outcomes, and included: treatment regimen, shortness of breath, steroid dose and likelihood of asthma flare-up.\n            \n            \n              Results\n              The final analysis dataset included 288 participants, 64\\% of whom preferred as-needed combination preventer and reliever. Of the attributes, no shortness of breath and lowest risk of asthma flare-up were ranked highest and second highest, respectively. However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment.\n            \n            \n              Conclusions\n              Knowledge of patient preferences for treatment attributes together with regimen characteristics can be used in shared decision-making regarding choice of treatment for patients with mild–moderate asthma.\n            \n            \n              Trial registration number\n              ACTRN12616000377437.},\n\tlanguage = {en},\n\tnumber = {10},\n\turldate = {2021-05-05},\n\tjournal = {Thorax},\n\tauthor = {Baggott, Christina and Hansen, Paul and Hancox, Robert J and Hardy, Jo Katherine and Sparks, Jenny and Holliday, Mark and Weatherall, Mark and Beasley, Richard and Reddel, Helen K and Fingleton, James},\n\tmonth = oct,\n\tyear = {2020},\n\tpages = {842--848},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma.\n \n \n \n\n\n \n Hardy, J.; Tewhaiti-Smith, J.; Baggott, C.; Fingleton, J.; Semprini, A.; Holliday, M.; Hancox, R. J.; Weatherall, M.; and Harwood, M.\n\n\n \n\n\n\n The New Zealand Medical Journal, 133(1520): 61–72. August 2020.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{hardy_combination_2020,\n\ttitle = {Combination budesonide/formoterol inhaler as sole reliever therapy in {Māori} and {Pacific} people with mild and moderate asthma},\n\tvolume = {133},\n\tissn = {1175-8716},\n\tabstract = {AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes.\nMETHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable.\nRESULTS: Seventy-two participants (8\\%) identified as Māori, 36 participants (4\\%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70).\nCONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.},\n\tlanguage = {eng},\n\tnumber = {1520},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Hardy, Jo and Tewhaiti-Smith, Jordan and Baggott, Christina and Fingleton, James and Semprini, Alex and Holliday, Mark and Hancox, Robert J. and Weatherall, Mark and Harwood, Matire},\n\tmonth = aug,\n\tyear = {2020},\n\tpmid = {32994594},\n\tkeywords = {Administration, Inhalation, Adult, Anti-Asthmatic Agents, Asthma, Bronchodilator Agents, Budesonide, Budesonide, Formoterol Fumarate Drug Combination, Case-Control Studies, Disease Progression, Drug Therapy, Combination, Ethnic Groups, Female, Humans, Male, Middle Aged, Nebulizers and Vaporizers, New Zealand, Outcome Assessment, Health Care, Terbutaline, Treatment Outcome},\n\tpages = {61--72},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n The Australasian Resuscitation In Sepsis Evaluation: Fluids or vasopressors in emergency department sepsis (ARISE FLUIDS), a multi‐centre observational study describing current practice in Australia and New Zealand.\n \n \n \n \n\n\n \n Keijzers, G.; Macdonald, S. P.; Udy, A. A; Arendts, G.; Bailey, M.; Bellomo, R.; Blecher, G. E; Burcham, J.; Coggins, A. R; Delaney, A.; Fatovich, D. M; Fraser, J. F; Harley, A.; Jones, P.; Kinnear, F. B; May, K.; Peake, S.; Taylor, D. M.; Williams, P.; the ARISE FLUIDS Observational Study Group; Nguyen, K.; Foong, L. H.; Hullick, C.; McNulty, R.; Na, A.; Trethewy, C.; Lutze, L.; Zhang, M.; Cowan, T.; Middleton, P.; Avis, S.; Vidler, S.; Salter, M.; Janes, S.; Delaney, A.; Harwood, T.; Oliver, M.; Jazayeri, F.; Jones, S.; Davoren, M.; Coggins, A.; Pradhananga, B.; Jones, P.; Newby, L.; Beck, S.; Sandleback, B.; Rabas, S.; Harger, S.; Tan, E.; Song, R.; Gutenstein, M.; Munro, A.; Connely, M.; Goodson, J.; Mclean, A.; Brabyn, C.; Mukerji, S.; Simmonds, H.; Young, P.; Sugeng, Y.; Bird, C.; McConnell, A.; Keijzers, G.; Henderson, P.; Johnson, D.; Perez, S.; Mahani, A.; Orda, U.; Thom, O.; Roberts, K.; Kinnear, F.; Hazelwood, S.; Pham, H.; Eley, R.; Livesay, G.; Devlin, M.; Murdoch, I.; Wood, E.; Williams, J.; Brown, N.; King, A.; Sadewasser, J.; Jones, L.; Gangathimmaiah, V.; Manudhane, A.; Haustead, D.; Ascencio‐Lane, J.; Taylor, D. M.; Buntine, P.; Walker, K.; Pouryahya, P.; Crompton, D.; Sultana, R.; Campbell, T.; Dwyer, R.; Blecher, G.; Knott, J.; Mitra, B.; Luckhoff, C.; Young, R.; Rudling, N.; Mukherjee, A.; Dyke, K.; Parker, C.; Arendts, G.; Cooper, A.; Nagree, Y.; Koay, K.; Kruger, C.; Ghedina, N.; Smedley, B.; Burcham, J.; Macdonald, S.; and Hamersley, H.\n\n\n \n\n\n\n Emergency Medicine Australasia, 32(4): 586–598. August 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"The$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{keijzers_australasian_2020,\n\ttitle = {The {Australasian} {Resuscitation} {In} {Sepsis} {Evaluation}: {Fluids} or vasopressors in emergency department sepsis ({ARISE} {FLUIDS}), a multi‐centre observational study describing current practice in {Australia} and {New} {Zealand}},\n\tvolume = {32},\n\tissn = {1742-6731, 1742-6723},\n\tshorttitle = {The {Australasian} {Resuscitation} {In} {Sepsis} {Evaluation}},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/1742-6723.13469},\n\tdoi = {10.1111/1742-6723.13469},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2021-05-05},\n\tjournal = {Emergency Medicine Australasia},\n\tauthor = {Keijzers, Gerben and Macdonald, Stephen PJ and Udy, Andrew A and Arendts, Glenn and Bailey, Michael and Bellomo, Rinaldo and Blecher, Gabriel E and Burcham, Jonathon and Coggins, Andrew R and Delaney, Anthony and Fatovich, Daniel M and Fraser, John F and Harley, Amanda and Jones, Peter and Kinnear, Frances B and May, Katya and Peake, Sandra and Taylor, David McD and Williams, Patricia and {the ARISE FLUIDS Observational Study Group} and Nguyen, Khanh and Foong, Lai Heng and Hullick, Carolyn and McNulty, Richard and Na, Andrew and Trethewy, Christopher and Lutze, Lucy and Zhang, Michael and Cowan, Tim and Middleton, Paul and Avis, Suzanne and Vidler, Sam and Salter, Mark and Janes, Simon and Delaney, Anthony and Harwood, Tom and Oliver, Matthew and Jazayeri, Farzad and Jones, Sarah and Davoren, Michael and Coggins, Andrew and Pradhananga, Bibhu and Jones, Peter and Newby, Lynette and Beck, Sierra and Sandleback, Brad and Rabas, Sophie and Harger, Simon and Tan, Eunicia and Song, Rima and Gutenstein, Marc and Munro, Andrew and Connely, Michael and Goodson, Jennifer and Mclean, Alastair and Brabyn, Christine and Mukerji, Saptarshi and Simmonds, Harnah and Young, Paul and Sugeng, Yulia and Bird, Cheryl and McConnell, Amanda and Keijzers, Gerben and Henderson, Peter and Johnson, David and Perez, Siegfried and Mahani, Abbas and Orda, Ulrich and Thom, Ogilvie and Roberts, Kym and Kinnear, Frances and Hazelwood, Sarah and Pham, Hanh and Eley, Rob and Livesay, Georgia and Devlin, Michael and Murdoch, Ian and Wood, Erik and Williams, Julian and Brown, Nathan and King, Alex and Sadewasser, Jan and Jones, Leonie and Gangathimmaiah, Vinay and Manudhane, Anit and Haustead, Daniel and Ascencio‐Lane, Juan‐Carlos and Taylor, David McD. and Buntine, Paul and Walker, Katie and Pouryahya, Pourya and Crompton, Daniel and Sultana, Ron and Campbell, Timothy and Dwyer, Rosamond and Blecher, Gabriel and Knott, Jonathan and Mitra, Biswadev and Luckhoff, Carl and Young, Russel and Rudling, Natalie and Mukherjee, Ashes and Dyke, Kerry‐Lee and Parker, Casey and Arendts, Glenn and Cooper, Alannah and Nagree, Yusuf and Koay, Keng and Kruger, Coert and Ghedina, Nicole and Smedley, Ben and Burcham, Jonathon and Macdonald, Stephen and Hamersley, Helen},\n\tmonth = aug,\n\tyear = {2020},\n\tpages = {586--598},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Neuromuscular blockade in patients with ARDS: a rapid practice guideline.\n \n \n \n \n\n\n \n Alhazzani, W.; Belley-Cote, E.; Møller, M. H.; Angus, D. C.; Papazian, L.; Arabi, Y. M.; Citerio, G.; Connolly, B.; Denehy, L.; Fox-Robichaud, A.; Hough, C. L.; Laake, J. H.; Machado, F. R.; Ostermann, M.; Piraino, T.; Sharif, S.; Szczeklik, W.; Young, P. J.; Gouskos, A.; Kiedrowski, K.; and Burns, K. E. A.\n\n\n \n\n\n\n Intensive Care Medicine, 46(11): 1977–1986. November 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Neuromuscular$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{alhazzani_neuromuscular_2020,\n\ttitle = {Neuromuscular blockade in patients with {ARDS}: a rapid practice guideline},\n\tvolume = {46},\n\tissn = {0342-4642, 1432-1238},\n\tshorttitle = {Neuromuscular blockade in patients with {ARDS}},\n\turl = {http://link.springer.com/10.1007/s00134-020-06227-8},\n\tdoi = {10.1007/s00134-020-06227-8},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2021-05-05},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Alhazzani, Waleed and Belley-Cote, E. and Møller, M. H. and Angus, D. C. and Papazian, L. and Arabi, Y. M. and Citerio, G. and Connolly, B. and Denehy, L. and Fox-Robichaud, A. and Hough, C. L. and Laake, J. H. and Machado, F. R. and Ostermann, M. and Piraino, T. and Sharif, S. and Szczeklik, W. and Young, P. J. and Gouskos, A. and Kiedrowski, K. and Burns, K. E. A.},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {1977--1986},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Efficacy of a topical herbal and mineral formulation (Dynamiclear) for the treatment of herpes simplex labialis in the community setting: study protocol for a randomised, double-blind placebo-controlled trial.\n \n \n \n \n\n\n \n Armour, M.; Semprini, A.; Ee, C.; MacCullagh, L.; and Shortt, N.\n\n\n \n\n\n\n BMJ Open, 10(1): e031876. January 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Efficacy$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n \n \n 3 downloads\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{armour_efficacy_2020,\n\ttitle = {Efficacy of a topical herbal and mineral formulation ({Dynamiclear}) for the treatment of herpes simplex labialis in the community setting: study protocol for a randomised, double-blind placebo-controlled trial},\n\tvolume = {10},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {Efficacy of a topical herbal and mineral formulation ({Dynamiclear}) for the treatment of herpes simplex labialis in the community setting},\n\turl = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2019-031876},\n\tdoi = {10.1136/bmjopen-2019-031876},\n\tabstract = {Introduction\n              Herpes simplex labialis (HSL) is a common infection that can cause painful lesions on the oral mucosa, commonly referred to as cold sores. Current biomedical treatments include topical aciclovir, which reduces the episode duration by an average of 0.5 days. This study will examine the efficacy and tolerability of an over-the-counter topical treatment, Dynamiclear in reducing duration and severity of HSL episodes.\n            \n            \n              Methods and analysis\n              \n                This prospective, randomised, double-blind, placebo-controlled, multi-centre trial will recruit a minimum of 292 adult participants across Australia and New Zealand who present with a cold sore within 48 hours of onset. They will be randomly allocated in a 2:1 ratio to receive either topical Dynamiclear (active) or placebo. Dynamiclear’s active ingredients are\n                Hypericum perforatum\n                ,\n                Calendula Officinalis\n                and copper sulfate. A single topical treatment of active or placebo will be applied by a pharmacy-based investigator, and participants will be provided with a viral swab kit to confirm presence of herpes virus 1 or 2 from ulcerated lesions. Participants will receive reminders by email and/or SMS to complete an online daily diary assessing their cold sore lesion using a visual guide, and recording other symptoms on numeric scales until healed. The primary outcome variable is median duration of HSL episode in days (participant evaluated) from presentation to return to normal skin. Secondary outcomes include severity of lesion pain, itching, burning and tingling during the symptomatic phase and proportion of lesions progressing to ulceration.\n              \n            \n            \n              Ethics and dissemination\n              Australian ethics approval from Western Sydney University Human Research Ethics Committee, ref: H12776. New Zealand Ethics approval from The Health and Disability Ethics Committees (HDEC) ref: 18/CEN/151. Results will be published in a peer-reviewed academic journal, presented at academic meetings and reported to participants\n            \n            \n              Trial registration numbers\n              Australia and New Zealand Clinical Trials Registry (ACTRN12618000890235); Universal Trial Number (UTN) (U1111-1233-2426).},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-05-05},\n\tjournal = {BMJ Open},\n\tauthor = {Armour, Mike and Semprini, Alex and Ee, Carolyn and MacCullagh, Lois and Shortt, Nick},\n\tmonth = jan,\n\tyear = {2020},\n\tpages = {e031876},\n}\n\n

\n

\n\n\n

\n Introduction Herpes simplex labialis (HSL) is a common infection that can cause painful lesions on the oral mucosa, commonly referred to as cold sores. Current biomedical treatments include topical aciclovir, which reduces the episode duration by an average of 0.5 days. This study will examine the efficacy and tolerability of an over-the-counter topical treatment, Dynamiclear in reducing duration and severity of HSL episodes. Methods and analysis This prospective, randomised, double-blind, placebo-controlled, multi-centre trial will recruit a minimum of 292 adult participants across Australia and New Zealand who present with a cold sore within 48 hours of onset. They will be randomly allocated in a 2:1 ratio to receive either topical Dynamiclear (active) or placebo. Dynamiclear’s active ingredients are Hypericum perforatum , Calendula Officinalis and copper sulfate. A single topical treatment of active or placebo will be applied by a pharmacy-based investigator, and participants will be provided with a viral swab kit to confirm presence of herpes virus 1 or 2 from ulcerated lesions. Participants will receive reminders by email and/or SMS to complete an online daily diary assessing their cold sore lesion using a visual guide, and recording other symptoms on numeric scales until healed. The primary outcome variable is median duration of HSL episode in days (participant evaluated) from presentation to return to normal skin. Secondary outcomes include severity of lesion pain, itching, burning and tingling during the symptomatic phase and proportion of lesions progressing to ulceration. Ethics and dissemination Australian ethics approval from Western Sydney University Human Research Ethics Committee, ref: H12776. New Zealand Ethics approval from The Health and Disability Ethics Committees (HDEC) ref: 18/CEN/151. Results will be published in a peer-reviewed academic journal, presented at academic meetings and reported to participants Trial registration numbers Australia and New Zealand Clinical Trials Registry (ACTRN12618000890235); Universal Trial Number (UTN) (U1111-1233-2426).\n

\n\n\n

\n \n\n \n \n \n \n \n \n Management of primary spontaneous pneumothorax: less is more.\n \n \n \n \n\n\n \n Brown, S.; Ball, E.; Lee, Y C G.; Beasley, R.; and Simpson, G.\n\n\n \n\n\n\n The Lancet, 396(10267): 1973. December 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Management$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{brown_management_2020,\n\ttitle = {Management of primary spontaneous pneumothorax: less is more},\n\tvolume = {396},\n\tissn = {01406736},\n\tshorttitle = {Management of primary spontaneous pneumothorax},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S014067362032674X},\n\tdoi = {10.1016/S0140-6736(20)32674-X},\n\tlanguage = {en},\n\tnumber = {10267},\n\turldate = {2021-04-28},\n\tjournal = {The Lancet},\n\tauthor = {Brown, Simon and Ball, Emma and Lee, Y C Gary and Beasley, Richard and Simpson, Graham},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {1973},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.\n \n \n \n \n\n\n \n Angus, D. C.; Berry, S.; Lewis, R. J.; Al-Beidh, F.; Arabi, Y.; van Bentum-Puijk, W.; Bhimani, Z.; Bonten, M.; Broglio, K.; Brunkhorst, F.; Cheng, A. C.; Chiche, J.; De Jong, M.; Detry, M.; Goossens, H.; Gordon, A.; Green, C.; Higgins, A. M.; Hullegie, S. J.; Kruger, P.; Lamontagne, F.; Litton, E.; Marshall, J.; McGlothlin, A.; McGuinness, S.; Mouncey, P.; Murthy, S.; Nichol, A.; O’Neill, G. K.; Parke, R.; Parker, J.; Rohde, G.; Rowan, K.; Turner, A.; Young, P.; Derde, L.; McArthur, C.; and Webb, S. A.\n\n\n \n\n\n\n Annals of the American Thoracic Society, 17(7): 879–891. July 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"The$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{angus_remap-cap_2020,\n\ttitle = {The {REMAP}-{CAP} ({Randomized} {Embedded} {Multifactorial} {Adaptive} {Platform} for {Community}-acquired {Pneumonia}) {Study}. {Rationale} and {Design}},\n\tvolume = {17},\n\tissn = {2329-6933, 2325-6621},\n\turl = {https://www.atsjournals.org/doi/10.1513/AnnalsATS.202003-192SD},\n\tdoi = {10.1513/AnnalsATS.202003-192SD},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2021-04-28},\n\tjournal = {Annals of the American Thoracic Society},\n\tauthor = {Angus, Derek C. and Berry, Scott and Lewis, Roger J. and Al-Beidh, Farah and Arabi, Yaseen and van Bentum-Puijk, Wilma and Bhimani, Zahra and Bonten, Marc and Broglio, Kristine and Brunkhorst, Frank and Cheng, Allen C. and Chiche, Jean-Daniel and De Jong, Menno and Detry, Michelle and Goossens, Herman and Gordon, Anthony and Green, Cameron and Higgins, Alisa M. and Hullegie, Sebastiaan J. and Kruger, Peter and Lamontagne, Francois and Litton, Edward and Marshall, John and McGlothlin, Anna and McGuinness, Shay and Mouncey, Paul and Murthy, Srinivas and Nichol, Alistair and O’Neill, Genevieve K. and Parke, Rachael and Parker, Jane and Rohde, Gernot and Rowan, Kathryn and Turner, Anne and Young, Paul and Derde, Lennie and McArthur, Colin and Webb, Steven A.},\n\tmonth = jul,\n\tyear = {2020},\n\tpages = {879--891},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.\n \n \n \n \n\n\n \n The Writing Committee for the REMAP-CAP Investigators; Angus, D. C.; Derde, L.; Al-Beidh, F.; Annane, D.; Arabi, Y.; Beane, A.; van Bentum-Puijk, W.; Berry, L.; Bhimani, Z.; Bonten, M.; Bradbury, C.; Brunkhorst, F.; Buxton, M.; Buzgau, A.; Cheng, A. C.; de Jong, M.; Detry, M.; Estcourt, L.; Fitzgerald, M.; Goossens, H.; Green, C.; Haniffa, R.; Higgins, A. M.; Horvat, C.; Hullegie, S. J.; Kruger, P.; Lamontagne, F.; Lawler, P. R.; Linstrum, K.; Litton, E.; Lorenzi, E.; Marshall, J.; McAuley, D.; McGlothin, A.; McGuinness, S.; McVerry, B.; Montgomery, S.; Mouncey, P.; Murthy, S.; Nichol, A.; Parke, R.; Parker, J.; Rowan, K.; Sanil, A.; Santos, M.; Saunders, C.; Seymour, C.; Turner, A.; van de Veerdonk, F.; Venkatesh, B.; Zarychanski, R.; Berry, S.; Lewis, R. J.; McArthur, C.; Webb, S. A.; and Gordon, A. C.\n\n\n \n\n\n\n JAMA, 324(13): 1317. October 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Effect$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{the_writing_committee_for_the_remap-cap_investigators_effect_2020,\n\ttitle = {Effect of {Hydrocortisone} on {Mortality} and {Organ} {Support} in {Patients} {With} {Severe} {COVID}-19: {The} {REMAP}-{CAP} {COVID}-19 {Corticosteroid} {Domain} {Randomized} {Clinical} {Trial}},\n\tvolume = {324},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of {Hydrocortisone} on {Mortality} and {Organ} {Support} in {Patients} {With} {Severe} {COVID}-19},\n\turl = {https://jamanetwork.com/journals/jama/fullarticle/2770278},\n\tdoi = {10.1001/jama.2020.17022},\n\tlanguage = {en},\n\tnumber = {13},\n\turldate = {2021-04-28},\n\tjournal = {JAMA},\n\tauthor = {{The Writing Committee for the REMAP-CAP Investigators} and Angus, Derek C. and Derde, Lennie and Al-Beidh, Farah and Annane, Djillali and Arabi, Yaseen and Beane, Abigail and van Bentum-Puijk, Wilma and Berry, Lindsay and Bhimani, Zahra and Bonten, Marc and Bradbury, Charlotte and Brunkhorst, Frank and Buxton, Meredith and Buzgau, Adrian and Cheng, Allen C. and de Jong, Menno and Detry, Michelle and Estcourt, Lise and Fitzgerald, Mark and Goossens, Herman and Green, Cameron and Haniffa, Rashan and Higgins, Alisa M. and Horvat, Christopher and Hullegie, Sebastiaan J. and Kruger, Peter and Lamontagne, Francois and Lawler, Patrick R. and Linstrum, Kelsey and Litton, Edward and Lorenzi, Elizabeth and Marshall, John and McAuley, Daniel and McGlothin, Anna and McGuinness, Shay and McVerry, Bryan and Montgomery, Stephanie and Mouncey, Paul and Murthy, Srinivas and Nichol, Alistair and Parke, Rachael and Parker, Jane and Rowan, Kathryn and Sanil, Ashish and Santos, Marlene and Saunders, Christina and Seymour, Christopher and Turner, Anne and van de Veerdonk, Frank and Venkatesh, Balasubramanian and Zarychanski, Ryan and Berry, Scott and Lewis, Roger J. and McArthur, Colin and Webb, Steven A. and Gordon, Anthony C.},\n\tmonth = oct,\n\tyear = {2020},\n\tpages = {1317},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Patient preferences for asthma management: a qualitative study.\n \n \n \n \n\n\n \n Baggott, C.; Chan, A.; Hurford, S.; Fingleton, J.; Beasley, R.; Harwood, M.; Reddel, H. K; and Levack, W. M. M.\n\n\n \n\n\n\n BMJ Open, 10(8): e037491. August 2020.\n Number: 8\n\n\n\n
\n\n\n\n \n \n $\"Patient$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{baggott_patient_2020-1,\n\ttitle = {Patient preferences for asthma management: a qualitative study},\n\tvolume = {10},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {Patient preferences for asthma management},\n\turl = {http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2020-037491},\n\tdoi = {10.1136/bmjopen-2020-037491},\n\tabstract = {Objective\n              Preference for asthma management and the use of medications is motivated by the interplay between lived experiences of asthma and patients’ attitudes towards medications. Many previous studies have focused on individual aspects of asthma management, such as the use of preventer and reliever inhalers. The aim of this qualitative study was to explore the preferences of patients with mild-moderate asthma for asthma management as a whole and factors that influenced these preferences.\n            \n            \n              Design\n              A qualitative study employing qualitative descriptive analysis situated within a constructionist epistemology to analyse transcribed audio recordings from focus groups.\n            \n            \n              Setting\n              Three locations within the greater Wellington area in New Zealand.\n            \n            \n              Participants\n              \n                Twenty-seven adults with self-reported doctor’s diagnosis of asthma, taking short-acting beta-agonists alone or inhaled corticosteroids with or without long-acting beta\n                2\n                -agonist, who had used any inhaled asthma medication within the last month.\n              \n            \n            \n              Results\n              Four key areas described preferences for asthma management. Preferences for self-management: participants wanted to be in control of their asthma and developed personal strategies to achieve this. Preferences for the specific medications or treatment regimen: participants preferred regimens that were convenient and reliably relieved symptoms. Preferences for inhaler devices: devices that had dose counters and were easy to use and portable were important. Preferences for asthma services: participants wanted easier access to their inhalers and to be empowered by their healthcare providers. Participant preferences within each of these four areas were influenced by the impact asthma had on their life, their health beliefs, emotional consequences of asthma and perceived barriers to asthma management.\n            \n            \n              Conclusions\n              This study illustrates the interaction of the lived experience of asthma, factors specific to the individual, and factors relating to asthma treatments in shaping patient preferences for asthma management. This aids our understanding of preferences for asthma management from the patient perspective.\n            \n            \n              Trial registration number\n              Australian New Zealand Clinical Trials Registry (ACTRN12619000601134).},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2020-09-03},\n\tjournal = {BMJ Open},\n\tauthor = {Baggott, Christina and Chan, Amy and Hurford, Sally and Fingleton, James and Beasley, Richard and Harwood, Matire and Reddel, Helen K and Levack, William Mark Magnus},\n\tmonth = aug,\n\tyear = {2020},\n\tnote = {Number: 8},\n\tpages = {e037491},\n}\n\n

\n

\n\n\n

\n Objective Preference for asthma management and the use of medications is motivated by the interplay between lived experiences of asthma and patients’ attitudes towards medications. Many previous studies have focused on individual aspects of asthma management, such as the use of preventer and reliever inhalers. The aim of this qualitative study was to explore the preferences of patients with mild-moderate asthma for asthma management as a whole and factors that influenced these preferences. Design A qualitative study employing qualitative descriptive analysis situated within a constructionist epistemology to analyse transcribed audio recordings from focus groups. Setting Three locations within the greater Wellington area in New Zealand. Participants Twenty-seven adults with self-reported doctor’s diagnosis of asthma, taking short-acting beta-agonists alone or inhaled corticosteroids with or without long-acting beta 2 -agonist, who had used any inhaled asthma medication within the last month. Results Four key areas described preferences for asthma management. Preferences for self-management: participants wanted to be in control of their asthma and developed personal strategies to achieve this. Preferences for the specific medications or treatment regimen: participants preferred regimens that were convenient and reliably relieved symptoms. Preferences for inhaler devices: devices that had dose counters and were easy to use and portable were important. Preferences for asthma services: participants wanted easier access to their inhalers and to be empowered by their healthcare providers. Participant preferences within each of these four areas were influenced by the impact asthma had on their life, their health beliefs, emotional consequences of asthma and perceived barriers to asthma management. Conclusions This study illustrates the interaction of the lived experience of asthma, factors specific to the individual, and factors relating to asthma treatments in shaping patient preferences for asthma management. This aids our understanding of preferences for asthma management from the patient perspective. Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12619000601134).\n

\n\n\n

\n \n\n \n \n \n \n \n \n Closed-Loop Oxygen Control Using a Novel Nasal High-Flow Device: A Randomized Crossover Trial.\n \n \n \n \n\n\n \n Harper, J. C.; Kearns, N. A; Maijers, I.; Bird, G. E; Braithwaite, I.; Shortt, N. P; Eathorne, A.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respiratory Care,respcare.08087. October 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Closed-Loop$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{harper_closed-loop_2020,\n\ttitle = {Closed-{Loop} {Oxygen} {Control} {Using} a {Novel} {Nasal} {High}-{Flow} {Device}: {A} {Randomized} {Crossover} {Trial}},\n\tissn = {0020-1324, 1943-3654},\n\tshorttitle = {Closed-{Loop} {Oxygen} {Control} {Using} a {Novel} {Nasal} {High}-{Flow} {Device}},\n\turl = {http://rc.rcjournal.com/lookup/doi/10.4187/respcare.08087},\n\tdoi = {10.4187/respcare.08087},\n\tlanguage = {en},\n\turldate = {2020-12-02},\n\tjournal = {Respiratory Care},\n\tauthor = {Harper, James CP and Kearns, Nethmi A and Maijers, Ingrid and Bird, Grace E and Braithwaite, Irene and Shortt, Nicholas P and Eathorne, Allie and Weatherall, Mark and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2020},\n\tpages = {respcare.08087},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Searching for the optimal oxygen saturation range in acutely unwell patients.\n \n \n \n \n\n\n \n Pilcher, J. M.; Kearns, C.; and Beasley, R.\n\n\n \n\n\n\n Emergency Medicine Journal,emermed–2020–210749. November 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Searching$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{pilcher_searching_2020,\n\ttitle = {Searching for the optimal oxygen saturation range in acutely unwell patients},\n\tissn = {1472-0205, 1472-0213},\n\turl = {https://emj.bmj.com/lookup/doi/10.1136/emermed-2020-210749},\n\tdoi = {10.1136/emermed-2020-210749},\n\tlanguage = {en},\n\turldate = {2020-11-27},\n\tjournal = {Emergency Medicine Journal},\n\tauthor = {Pilcher, Janine Marie and Kearns, Ciléin and Beasley, Richard},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {emermed--2020--210749},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Influenza control during the COVID-19 pandemic.\n \n \n \n \n\n\n \n Hills, T.; Kearns, N.; Kearns, C.; and Beasley, R.\n\n\n \n\n\n\n The Lancet. October 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Influenza$ Paper\n \n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{hills_influenza_2020,\n\ttitle = {Influenza control during the {COVID}-19 pandemic},\n\turl = {https://doi.org/10.1016/S0140-6736(20)32166-8},\n\turldate = {2020-10-23},\n\tjournal = {The Lancet},\n\tauthor = {Hills, Thomas and Kearns, Nethmi and Kearns, Ciléin and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2020},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial.\n \n \n \n \n\n\n \n Baggott, C.; Hardy, J.; Sparks, J.; Holliday, M.; Hall, D.; Vohlidkova, A.; Hancox, R. J.; Weatherall, M.; Fingleton, J.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal, 56(4): 2000170. October 2020.\n Number: 4\n\n\n\n
\n\n\n\n \n \n $\"Self-titration$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{baggott_self-titration_2020,\n\ttitle = {Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the {PRACTICAL} randomised controlled trial},\n\tvolume = {56},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Self-titration of inhaled corticosteroid and β $_{\\textrm{2}}$ -agonist in response to symptoms in mild asthma},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00170-2020},\n\tdoi = {10.1183/13993003.00170-2020},\n\tabstract = {Introduction\n              \n                In mild asthma, as-needed budesonide–formoterol is superior or noninferior to maintenance budesonide plus as-needed short-acting β\n                2\n                -agonist in reducing severe exacerbations. In this pre-specified analysis, we investigated patterns of inhaled corticosteroid (ICS) and β\n                2\n                -agonist use in PRACTICAL, a randomised controlled trial.\n              \n            \n            \n              Methods\n              \n                Participants were randomised 1:1 to as-needed budesonide–formoterol (200/6 μg Turbuhaler, one actuation) or maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations) for 52 weeks. 110 participants had electronic monitors attached to their study inhalers which captured the time and date of every actuation. Key outcome measures were patterns of ICS and β\n                2\n                -agonist use. One actuation of budesonide–formoterol was considered to be an equivalent bronchodilator dose as two actuations of terbutaline.\n              \n            \n            \n              Results\n              \n                Participants randomised to as-needed budesonide–formoterol had more days with no ICS use compared with maintenance budesonide (median total days of no use 156\n                versus\n                22 days, respectively), lower median daily budesonide dose (164\n                versus\n                328 μg, respectively) and a greater median number of days of ≥4 budesonide actuations (4\n                versus\n                1 days, respectively). Participants randomised to as-needed budesonide–formoterol took higher equivalent doses of β\n                2\n                -agonist both overall (median number of actuations 0.8\n                versus\n                0.3 per day, respectively) and in response to worsening asthma (total number of “overuse days” of {\\textgreater}8 or {\\textgreater}16 actuations of budesonide–formoterol or terbutaline 33\n                versus\n                10 days, respectively).\n              \n            \n            \n              Conclusions\n              \n                The timing of ICS dose when self-titrated to β\n                2\n                -agonist use is more important than total ICS dose in reducing severe exacerbation risk in mild asthma, when associated with greater overall use of as-needed β\n                2\n                -agonist.},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2020-10-13},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Baggott, Christina and Hardy, Jo and Sparks, Jenny and Holliday, Mark and Hall, Daniela and Vohlidkova, Alexandra and Hancox, Robert J. and Weatherall, Mark and Fingleton, James and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2020},\n\tnote = {Number: 4},\n\tpages = {2000170},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Taking Charge: A Proposed Psychological Intervention to Improve Pulmonary Rehabilitation Outcomes for People with COPD.\n \n \n \n \n\n\n \n McNaughton, A.; Levack, W.; and McNaughton, H.\n\n\n \n\n\n\n International Journal of Chronic Obstructive Pulmonary Disease, Volume 15: 2127–2133. September 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Taking$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{mcnaughton_taking_2020,\n\ttitle = {Taking {Charge}: {A} {Proposed} {Psychological} {Intervention} to {Improve} {Pulmonary} {Rehabilitation} {Outcomes} for {People} with {COPD}},\n\tvolume = {Volume 15},\n\tissn = {1178-2005},\n\tshorttitle = {Taking {Charge}},\n\turl = {https://www.dovepress.com/taking-charge-a-proposed-psychological-intervention-to-improve-pulmona-peer-reviewed-article-COPD},\n\tdoi = {10.2147/COPD.S267268},\n\tlanguage = {en},\n\turldate = {2020-09-14},\n\tjournal = {International Journal of Chronic Obstructive Pulmonary Disease},\n\tauthor = {McNaughton, Amanda and Levack, William and McNaughton, Harry},\n\tmonth = sep,\n\tyear = {2020},\n\tpages = {2127--2133},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n The Taking Charge After Stroke Study: How We Tested a Community Stroke Rehabilitation Intervention in a Randomized Controlled Trial.\n \n \n \n \n\n\n \n Fu, V. W. Y.; and McNaughton, H.\n\n\n \n\n\n\n SAGE Publications Ltd, 1 Oliver's Yard, 55 City Road, London EC1Y 1SP United Kingdom, 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"The$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@book{fu_taking_2020,\n\taddress = {1 Oliver's Yard, 55 City Road, London EC1Y 1SP United Kingdom},\n\ttitle = {The {Taking} {Charge} {After} {Stroke} {Study}: {How} {We} {Tested} a {Community} {Stroke} {Rehabilitation} {Intervention} in a {Randomized} {Controlled} {Trial}},\n\tisbn = {978-1-5297-3093-7},\n\tshorttitle = {The {Taking} {Charge} {After} {Stroke} {Study}},\n\turl = {https://methods.sagepub.com/case/taking-charge-after-stroke-community-stroke-rehabilitation-intervention-rct},\n\turldate = {2020-09-14},\n\tpublisher = {SAGE Publications Ltd},\n\tauthor = {Fu, Vivian Wai Yin and McNaughton, Harry},\n\tyear = {2020},\n\tdoi = {10.4135/9781529730937},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Taking Charge after Stroke: A randomized controlled trial of a person-centered, self-directed rehabilitation intervention.\n \n \n \n \n\n\n \n Fu, V.; Weatherall, M.; McPherson, K.; Taylor, W.; McRae, A.; Thomson, T.; Gommans, J.; Green, G.; Harwood, M.; Ranta, A.; Hanger, C.; Riley, J.; and McNaughton, H.\n\n\n \n\n\n\n International Journal of Stroke,174749302091514. April 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Taking$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{fu_taking_2020-1,\n\ttitle = {Taking {Charge} after {Stroke}: {A} randomized controlled trial of a person-centered, self-directed rehabilitation intervention},\n\tissn = {1747-4930, 1747-4949},\n\tshorttitle = {Taking {Charge} after {Stroke}},\n\turl = {http://journals.sagepub.com/doi/10.1177/1747493020915144},\n\tdoi = {10.1177/1747493020915144},\n\tabstract = {Background and purpose\n              “Take Charge” is a novel, community-based self-directed rehabilitation intervention which helps a person with stroke take charge of their own recovery. In a previous randomized controlled trial, a single Take Charge session improved independence and health-related quality of life 12 months following stroke in Māori and Pacific New Zealanders. We tested the same intervention in three doses (zero, one, or two sessions) in a larger study and in a broader non-Māori and non-Pacific population with stroke. We aimed to confirm whether the Take Charge intervention improved quality of life at 12 months after stroke in a different population and whether two sessions were more effective than one.\n            \n            \n              Methods\n              We randomized 400 people within 16 weeks of acute stroke who had been discharged to institution-free community living at seven centers in New Zealand to a single Take Charge session (TC1, n = 132), two Take Charge sessions six weeks apart (TC2, n = 138), or a control intervention (n = 130). Take Charge is a “talking therapy” that encourages a sense of purpose, autonomy, mastery, and connectedness with others. The primary outcome was the Physical Component Summary score of the Short Form 36 at 12 months following stroke comparing any Take Charge intervention to control.\n            \n            \n              Results\n              Of the 400 people randomized (mean age 72.2 years, 58.5\\% male), 10 died and two withdrew from the study. The remaining 388 (97\\%) people were followed up at 12 months after stroke. Twelve months following stroke, participants in either of the TC groups (i.e. TC1 + TC2) scored 2.9 (95\\% confidence intervals (CI) 0.95 to 4.9, p = 0.004) points higher (better) than control on the Short Form 36 Physical Component Summary. This difference remained significant when adjusted for pre-specified baseline variables. There was a dose effect with Short Form 36 Physical Component Summary scores increasing by 1.9 points (95\\% CI 0.8 to 3.1, p {\\textless} 0.001) for each extra Take Charge session received. Exposure to the Take Charge intervention was associated with reduced odds of being dependent (modified Rankin Scale 3 to 5) at 12 months (TC1 + TC2 12\\% versus control 19.5\\%, odds ratio 0.55, 95\\% CI 0.31 to 0.99, p = 0.045).\n            \n            \n              Conclusions\n              Confirming the previous randomized controlled trial outcome, Take Charge—a low-cost, person-centered, self-directed rehabilitation intervention after stroke—improved health-related quality of life and independence.\n            \n            \n              Clinical trial registration-URL\n              http://www.anzctr.org.au . Unique identifier: ACTRN12615001163594},\n\tlanguage = {en},\n\turldate = {2020-09-14},\n\tjournal = {International Journal of Stroke},\n\tauthor = {Fu, Vivian and Weatherall, Mark and McPherson, Kathryn and Taylor, William and McRae, Anna and Thomson, Tom and Gommans, John and Green, Geoff and Harwood, Matire and Ranta, Annemarei and Hanger, Carl and Riley, Judith and McNaughton, Harry},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {174749302091514},\n}\n\n

\n

\n\n\n

\n Background and purpose “Take Charge” is a novel, community-based self-directed rehabilitation intervention which helps a person with stroke take charge of their own recovery. In a previous randomized controlled trial, a single Take Charge session improved independence and health-related quality of life 12 months following stroke in Māori and Pacific New Zealanders. We tested the same intervention in three doses (zero, one, or two sessions) in a larger study and in a broader non-Māori and non-Pacific population with stroke. We aimed to confirm whether the Take Charge intervention improved quality of life at 12 months after stroke in a different population and whether two sessions were more effective than one. Methods We randomized 400 people within 16 weeks of acute stroke who had been discharged to institution-free community living at seven centers in New Zealand to a single Take Charge session (TC1, n = 132), two Take Charge sessions six weeks apart (TC2, n = 138), or a control intervention (n = 130). Take Charge is a “talking therapy” that encourages a sense of purpose, autonomy, mastery, and connectedness with others. The primary outcome was the Physical Component Summary score of the Short Form 36 at 12 months following stroke comparing any Take Charge intervention to control. Results Of the 400 people randomized (mean age 72.2 years, 58.5% male), 10 died and two withdrew from the study. The remaining 388 (97%) people were followed up at 12 months after stroke. Twelve months following stroke, participants in either of the TC groups (i.e. TC1 + TC2) scored 2.9 (95% confidence intervals (CI) 0.95 to 4.9, p = 0.004) points higher (better) than control on the Short Form 36 Physical Component Summary. This difference remained significant when adjusted for pre-specified baseline variables. There was a dose effect with Short Form 36 Physical Component Summary scores increasing by 1.9 points (95% CI 0.8 to 3.1, p \\textless 0.001) for each extra Take Charge session received. Exposure to the Take Charge intervention was associated with reduced odds of being dependent (modified Rankin Scale 3 to 5) at 12 months (TC1 + TC2 12% versus control 19.5%, odds ratio 0.55, 95% CI 0.31 to 0.99, p = 0.045). Conclusions Confirming the previous randomized controlled trial outcome, Take Charge—a low-cost, person-centered, self-directed rehabilitation intervention after stroke—improved health-related quality of life and independence. Clinical trial registration-URL http://www.anzctr.org.au . Unique identifier: ACTRN12615001163594\n

\n\n\n

\n \n\n \n \n \n \n \n \n Reducing the burden of asthma: time to set research and clinical priorities.\n \n \n \n \n\n\n \n Beasley, R.; and Hancox, R. J\n\n\n \n\n\n\n The Lancet Respiratory Medicine,S2213260020304008. September 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Reducing$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_reducing_2020,\n\ttitle = {Reducing the burden of asthma: time to set research and clinical priorities},\n\tissn = {22132600},\n\tshorttitle = {Reducing the burden of asthma},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260020304008},\n\tdoi = {10.1016/S2213-2600(20)30400-8},\n\tlanguage = {en},\n\turldate = {2020-09-11},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Hancox, Robert J},\n\tmonth = sep,\n\tyear = {2020},\n\tpages = {S2213260020304008},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand.\n \n \n \n \n\n\n \n Warrillow, S.; Fisher, C.; Tibballs, H.; Bailey, M.; McArthur, C.; Lawson‐Smith, P.; Prasad, B.; Anstey, M.; Venkatesh, B.; Dashwood, G.; Walsham, J.; Holt, A.; Wiersema, U.; Gattas, D.; Zoeller, M.; Garcia Alvarez, M.; and Bellomo, R.\n\n\n \n\n\n\n Journal of Gastroenterology and Hepatology, 35(5): 846–854. May 2020.\n Number: 5\n\n\n\n
\n\n\n\n \n \n $\"Coagulation$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{warrillow_coagulation_2020,\n\ttitle = {Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in {Australia} and {New} {Zealand}},\n\tvolume = {35},\n\tissn = {0815-9319, 1440-1746},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.14876},\n\tdoi = {10.1111/jgh.14876},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Gastroenterology and Hepatology},\n\tauthor = {Warrillow, Stephen and Fisher, Caleb and Tibballs, Heath and Bailey, Michael and McArthur, Colin and Lawson‐Smith, Pia and Prasad, Bheemasenachar and Anstey, Matthew and Venkatesh, Bala and Dashwood, Gemma and Walsham, James and Holt, Andrew and Wiersema, Ubbo and Gattas, David and Zoeller, Matthew and Garcia Alvarez, Mercedes and Bellomo, Rinaldo},\n\tmonth = may,\n\tyear = {2020},\n\tnote = {Number: 5},\n\tpages = {846--854},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Nasal gene expression changes with inhaled corticosteroid treatment in asthma.\n \n \n \n\n\n \n Boudewijn, I. M.; Lan, A.; Faiz, A.; Cox, C. A.; Brouwer, S.; Schokker, S.; Vroegop, S. J.; Nawijn, M. C.; Woodruff, P. G.; Christenson, S. A.; Hagedoorn, P.; Frijlink, H. W.; Choy, D. F.; Brouwer, U.; Wisman, M.; Postma, D. S.; Fingleton, J.; Beasley, R.; van den Berge, M.; and Guryev, V.\n\n\n \n\n\n\n Allergy, 75(1): 191–194. 2020.\n Number: 1\n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{boudewijn_nasal_2020,\n\ttitle = {Nasal gene expression changes with inhaled corticosteroid treatment in asthma},\n\tvolume = {75},\n\tissn = {1398-9995},\n\tdoi = {10.1111/all.13952},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {Allergy},\n\tauthor = {Boudewijn, Ilse M. and Lan, Andy and Faiz, Alen and Cox, Claire A. and Brouwer, Sharon and Schokker, Siebrig and Vroegop, Sebastiaan J. and Nawijn, Martijn C. and Woodruff, Prescott G. and Christenson, Stephanie A. and Hagedoorn, Paul and Frijlink, Henderik W. and Choy, David F. and Brouwer, Uilke and Wisman, Marissa and Postma, Dirkje S. and Fingleton, James and Beasley, Richard and van den Berge, Maarten and Guryev, Victor},\n\tyear = {2020},\n\tpmid = {31230369},\n\tnote = {Number: 1},\n\tpages = {191--194},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury.\n \n \n \n \n\n\n \n The STARRT-AKI Investigators\n\n\n \n\n\n\n New England Journal of Medicine, 383(3): 240–251. July 2020.\n Number: 3\n\n\n\n
\n\n\n\n \n \n $\"Timing$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{the_starrt-aki_investigators_timing_2020,\n\ttitle = {Timing of {Initiation} of {Renal}-{Replacement} {Therapy} in {Acute} {Kidney} {Injury}},\n\tvolume = {383},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa2000741},\n\tdoi = {10.1056/NEJMoa2000741},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {{The STARRT-AKI Investigators}},\n\tmonth = jul,\n\tyear = {2020},\n\tnote = {Number: 3},\n\tpages = {240--251},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Conservative Oxygen Therapy during Mechanical Ventilation in the ICU.\n \n \n \n \n\n\n \n The ICU-ROX Investigators; Australian, t.; and Group, N. Z. I. C. S. C. T.\n\n\n \n\n\n\n New England Journal of Medicine, 382(11): 989–998. March 2020.\n Number: 11\n\n\n\n
\n\n\n\n \n \n $\"Conservative$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{the_icu-rox_investigators_and_the_australian_and_new_zealand_intensive_care_society_clinical_trials_group_conservative_2020,\n\ttitle = {Conservative {Oxygen} {Therapy} during {Mechanical} {Ventilation} in the {ICU}},\n\tvolume = {382},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1903297},\n\tdoi = {10.1056/NEJMoa1903297},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {{The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group}},\n\tmonth = mar,\n\tyear = {2020},\n\tnote = {Number: 11},\n\tpages = {989--998},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.\n \n \n \n \n\n\n \n The PEPTIC Investigators for the Australian; New Zealand Intensive Care Society Clinical Trials Group, A. H. S. C. C. S. C. N.; Group, t. I. C. C. T.; Young, P. J.; Bagshaw, S. M.; Forbes, A. B.; Nichol, A. D.; Wright, S. E.; Bailey, M.; Bellomo, R.; Beasley, R.; Brickell, K.; Eastwood, G. M.; Gattas, D. J.; van Haren, F.; Litton, E.; Mackle, D. M.; McArthur, C. J.; McGuinness, S. P.; Mouncey, P. R.; Navarra, L.; Opgenorth, D.; Pilcher, D.; Saxena, M. K.; Webb, S. A.; Wiley, D.; and Rowan, K. M.\n\n\n \n\n\n\n JAMA, 323(7): 616. February 2020.\n Number: 7\n\n\n\n
\n\n\n\n \n \n $\"Effect$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{the_peptic_investigators_for_the_australian_and_new_zealand_intensive_care_society_clinical_trials_group_alberta_health_services_critical_care_strategic_clinical_network_and_the_irish_critical_care_trials_group_effect_2020,\n\ttitle = {Effect of {Stress} {Ulcer} {Prophylaxis} {With} {Proton} {Pump} {Inhibitors} vs {Histamine}-2 {Receptor} {Blockers} on {In}-{Hospital} {Mortality} {Among} {ICU} {Patients} {Receiving} {Invasive} {Mechanical} {Ventilation}: {The} {PEPTIC} {Randomized} {Clinical} {Trial}},\n\tvolume = {323},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of {Stress} {Ulcer} {Prophylaxis} {With} {Proton} {Pump} {Inhibitors} vs {Histamine}-2 {Receptor} {Blockers} on {In}-{Hospital} {Mortality} {Among} {ICU} {Patients} {Receiving} {Invasive} {Mechanical} {Ventilation}},\n\turl = {https://jamanetwork.com/journals/jama/fullarticle/2759412},\n\tdoi = {10.1001/jama.2019.22190},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2020-08-23},\n\tjournal = {JAMA},\n\tauthor = {{The PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, and the Irish Critical Care Trials Group} and Young, Paul J. and Bagshaw, Sean M. and Forbes, Andrew B. and Nichol, Alistair D. and Wright, Stephen E. and Bailey, Michael and Bellomo, Rinaldo and Beasley, Richard and Brickell, Kathy and Eastwood, Glenn M. and Gattas, David J. and van Haren, Frank and Litton, Edward and Mackle, Diane M. and McArthur, Colin J. and McGuinness, Shay P. and Mouncey, Paul R. and Navarra, Leanlove and Opgenorth, Dawn and Pilcher, David and Saxena, Manoj K. and Webb, Steve A. and Wiley, Daisy and Rowan, Kathryn M.},\n\tmonth = feb,\n\tyear = {2020},\n\tnote = {Number: 7},\n\tpages = {616},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Anti‐inflammatory reliever therapy in asthma: The evidence mounts but more is needed.\n \n \n \n \n\n\n \n Bruce, P.; Hatter, L.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 25(8): 776–778. August 2020.\n Number: 8\n\n\n\n
\n\n\n\n \n \n $\"Anti‐inflammatory$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{bruce_antiinflammatory_2020,\n\ttitle = {Anti‐inflammatory reliever therapy in asthma: {The} evidence mounts but more is needed},\n\tvolume = {25},\n\tissn = {1323-7799, 1440-1843},\n\tshorttitle = {Anti‐inflammatory reliever therapy in asthma},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13889},\n\tdoi = {10.1111/resp.13889},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2020-07-15},\n\tjournal = {Respirology},\n\tauthor = {Bruce, Pepa and Hatter, Lee and Beasley, Richard},\n\tmonth = aug,\n\tyear = {2020},\n\tnote = {Number: 8},\n\tpages = {776--778},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Medical cannabis: knowledge and expectations in a cohort of North Island New Zealand general practitioners.\n \n \n \n\n\n \n Oldfield, K.; Braithwaite, I.; Beasley, R.; Eathorne, A.; Newton-Howes, G.; and Semprini, A.\n\n\n \n\n\n\n The New Zealand Medical Journal, 133(1508): 12–28. 2020.\n Number: 1508\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{oldfield_medical_2020,\n\ttitle = {Medical cannabis: knowledge and expectations in a cohort of {North} {Island} {New} {Zealand} general practitioners},\n\tvolume = {133},\n\tissn = {1175-8716},\n\tshorttitle = {Medical cannabis},\n\tabstract = {AIM: To investigate GP knowledge of the use of cannabis as a medicine and its regulation in New Zealand.\nMETHOD: A convenience sample of GPs completed a questionnaire during continuing medical education sessions. Key domains investigated were: patient interactions around use of cannabis as a medicine; prescription facilitation and impediments; knowledge of evidence for and against the use of cannabis as a medicine; knowledge of the New Zealand regulatory processes and knowledge of pharmaceutical grade products. Questionnaires were administered between June and October 2018.\nRESULTS: There were 42/76 (55\\%) GPs who stated at least one patient had asked for a cannabis prescription for medical use in the last 12 months and 43/76 (57\\%) were aware of pharmaceutical grade preparations, the majority Sativex. There were 59/75 (79\\%) who expressed concerns about future prescribing; however, 63/75 (84\\%) indicated they would be 'somewhat' or 'very' likely to prescribe a PHARMAC-funded product with good evidence in specific conditions.\nCONCLUSION: Some GPs have concerns about prescribing medicinal cannabis. Due to regulatory restrictions, including no currently funded products, and uncertain scientific evidence of efficacy and safety, education programmes will be required to inform the medico-legal, evidential and practical elements of prescribing cannabis as a medicine.},\n\tlanguage = {eng},\n\tnumber = {1508},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Oldfield, Karen and Braithwaite, Irene and Beasley, Richard and Eathorne, Allie and Newton-Howes, Giles and Semprini, Alex},\n\tyear = {2020},\n\tpmid = {31945040},\n\tnote = {Number: 1508},\n\tkeywords = {Adult, Aged, Aged, 80 and over, Cannabis, Education, Medical, Continuing, Female, General Practitioners, Humans, Knowledge, Male, Medical Marijuana, Middle Aged, Motivation, New Zealand, Patient Safety, Surveys and Questionnaires, Treatment Outcome},\n\tpages = {12--28},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Cannabis-based medicinal products in arthritis, a painful conundrum.\n \n \n \n\n\n \n Berg, M. V. d.; John, M.; Black, M.; Semprini, A.; Oldfield, K.; Glass, M.; and Braithwaite, I.\n\n\n \n\n\n\n The New Zealand Medical Journal, 133(1515): 35–45. May 2020.\n Number: 1515\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{berg_cannabis-based_2020,\n\ttitle = {Cannabis-based medicinal products in arthritis, a painful conundrum},\n\tvolume = {133},\n\tissn = {1175-8716},\n\tabstract = {AIMS: The changing medicolegal climate regarding the medicinal use of cannabinoids in New Zealand will increase the likelihood of patients consulting general practitioners (GPs) about these products. Arthritis is a common medical condition for which cannabis-based products are promoted and used; however, doctors' knowledge about the efficacy and safety of these products in the setting of arthritis may be limited.\nMETHODS: We undertook a rapid review of the medical literature on cannabis-based medicinal products in arthritis.\nRESULTS: Animal studies have identified endocannabinoid pathways in arthritis that are potentially amenable to interventions. One randomised placebo-controlled trial of Sativex® in adults with rheumatoid arthritis has shown some improvements in pain but not in comparison with a standardised pharmacological treatment regimen. Systematic reviews of cannabis-based products in arthritis have determined that there is currently insufficient evidence to recommend cannabis-based medicines for routine clinical use. There were five ongoing registered clinical trials of cannabis-based products in arthritis, the results of which are yet to be reported.\nCONCLUSIONS: While animal models have identified possible endocannabinoid pathways in arthritis, there is no clear evidence of benefit in humans or comparative efficacy with current treatments. At this stage, there is little evidence to support GPs prescribing cannabis-based medicinal products for arthritis.},\n\tlanguage = {eng},\n\tnumber = {1515},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Berg, Marthe Van den and John, Mary and Black, Melissa and Semprini, Alex and Oldfield, Karen and Glass, Michelle and Braithwaite, Irene},\n\tmonth = may,\n\tyear = {2020},\n\tpmid = {32438375},\n\tnote = {Number: 1515},\n\tpages = {35--45},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Medicinal applications of cannabis/cannabinoids.\n \n \n \n \n\n\n \n Braithwaite, I.; Bhagavan, C.; Doppen, M.; Kung, S.; Oldfield, K.; and Newton-Howes, G.\n\n\n \n\n\n\n Current Opinion in Psychology, 38: 1–10. April 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Medicinal$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{braithwaite_medicinal_2020,\n\ttitle = {Medicinal applications of cannabis/cannabinoids},\n\tvolume = {38},\n\tissn = {2352250X},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2352250X20300981},\n\tdoi = {10.1016/j.copsyc.2020.06.002},\n\tlanguage = {en},\n\turldate = {2020-07-13},\n\tjournal = {Current Opinion in Psychology},\n\tauthor = {Braithwaite, Irene and Bhagavan, Chiranth and Doppen, Marjan and Kung, Stacey and Oldfield, Karen and Newton-Howes, Giles},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {1--10},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n The history and future of short‐acting beta 2 ‐agonist therapy in asthma.\n \n \n \n \n\n\n \n Hills, T.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 25(3): 246–248. March 2020.\n Number: 3\n\n\n\n
\n\n\n\n \n \n $\"The$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{hills_history_2020,\n\ttitle = {The history and future of short‐acting beta 2 ‐agonist therapy in asthma},\n\tvolume = {25},\n\tissn = {1323-7799},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13727},\n\tdoi = {10.1111/resp.13727},\n\tnumber = {3},\n\tjournal = {Respirology},\n\tauthor = {Hills, Thomas and Beasley, Richard},\n\tmonth = mar,\n\tyear = {2020},\n\tnote = {Number: 3},\n\tpages = {246--248},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.\n \n \n \n \n\n\n \n Maijers, I.; Kearns, N.; Harper, J.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal, 55(1): 1901147. January 2020.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"Oral$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n\n\n\n

\n

@article{maijers_oral_2020,\n\ttitle = {Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma},\n\tvolume = {55},\n\tissn = {0903-1936},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01147-2019},\n\tdoi = {10.1183/13993003.01147-2019},\n\tnumber = {1},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Maijers, Ingrid and Kearns, Nethmi and Harper, James and Weatherall, Mark and Beasley, Richard},\n\tmonth = jan,\n\tyear = {2020},\n\tnote = {Number: 1},\n\tkeywords = {Asthma},\n\tpages = {1901147},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Optimal Asthma Control: Time for a New Target.\n \n \n \n \n\n\n \n Beasley, R.; Braithwaite, I.; Semprini, A.; Kearns, C.; Weatherall, M.; and Pavord, I. D\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine,rccm.201910–1934CI. January 2020.\n \n\n\n\n
\n\n\n\n \n \n $\"Optimal$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n\n\n\n

\n

@article{beasley_optimal_2020,\n\ttitle = {Optimal {Asthma} {Control}: {Time} for a {New} {Target}},\n\tissn = {1073-449X},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.201910-1934CI},\n\tdoi = {10.1164/rccm.201910-1934CI},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Braithwaite, Irene and Semprini, Alex and Kearns, Ciléin and Weatherall, Mark and Pavord, Ian D},\n\tmonth = jan,\n\tyear = {2020},\n\tkeywords = {Asthma},\n\tpages = {rccm.201910--1934CI},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Conservative versus Interventional Treatment for Spontaneous Pneumothorax.\n \n \n \n \n\n\n \n Brown, S. G.; Ball, E. L.; Perrin, K.; Asha, S. E.; Braithwaite, I.; Egerton-Warburton, D.; Jones, P. G.; Keijzers, G.; Kinnear, F. B.; Kwan, B. C.; Lam, K.; Lee, Y. G.; Nowitz, M.; Read, C. A.; Simpson, G.; Smith, J. A.; Summers, Q. A.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n New England Journal of Medicine, 382(5): 405–415. January 2020.\n Number: 5\n\n\n\n
\n\n\n\n \n \n $\"Conservative$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{brown_conservative_2020,\n\ttitle = {Conservative versus {Interventional} {Treatment} for {Spontaneous} {Pneumothorax}},\n\tvolume = {382},\n\tissn = {0028-4793},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1910775},\n\tdoi = {10.1056/NEJMoa1910775},\n\tnumber = {5},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Brown, Simon G.A. and Ball, Emma L. and Perrin, Kyle and Asha, Stephen E. and Braithwaite, Irene and Egerton-Warburton, Diana and Jones, Peter G. and Keijzers, Gerben and Kinnear, Frances B. and Kwan, Ben C.H. and Lam, K.V. and Lee, Y.C. Gary and Nowitz, Mike and Read, Catherine A. and Simpson, Graham and Smith, Julian A. and Summers, Quentin A. and Weatherall, Mark and Beasley, Richard},\n\tmonth = jan,\n\tyear = {2020},\n\tnote = {Number: 5},\n\tpages = {405--415},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Achieving the balance between evidence and simplicity.\n \n \n \n \n\n\n \n Beasley, R.; Braithwaite, I.; Semprini, A.; Kearns, C.; Weatherall, M.; Harrison, T.; Papi, A.; and Pavord, I. D.\n\n\n \n\n\n\n European Respiratory Journal, 55(4): 2000651. April 2020.\n Number: 4\n\n\n\n
\n\n\n\n \n \n $\"Achieving$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_achieving_2020,\n\ttitle = {Achieving the balance between evidence and simplicity},\n\tvolume = {55},\n\tissn = {0903-1936, 1399-3003},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00651-2020},\n\tdoi = {10.1183/13993003.00651-2020},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2020-05-01},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Beasley, Richard and Braithwaite, Irene and Semprini, Alex and Kearns, Ciléin and Weatherall, Mark and Harrison, Tim and Papi, Alberto and Pavord, Ian D.},\n\tmonth = apr,\n\tyear = {2020},\n\tnote = {Number: 4},\n\tpages = {2000651},\n}\n

\n

\n\n\n\n